Evolus, Inc. (NASDAQ:EOLS) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Stanley Muller on May 23rd, 2026

Shares of Evolus, Inc. (NASDAQ:EOLS – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $16.00.

EOLS has been the subject of several research reports. Wall Street Zen downgraded shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. HC Wainwright lowered their target price on shares of Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Mizuho set a $15.00 target price on Evolus in a research note on Wednesday, February 4th. Finally, BTIG Research reiterated a “buy” rating and set a $13.00 target price on shares of Evolus in a research report on Wednesday, March 4th.

View Our Latest Report on Evolus

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 13,669 shares of the stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $4.75, for a total transaction of $64,927.75. Following the transaction, the insider directly owned 604,700 shares in the company, valued at $2,872,325. This represents a 2.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rui Avelar sold 29,996 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the transaction, the insider directly owned 430,542 shares of the company’s stock, valued at $2,105,350.38. This trade represents a 6.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 163,504 shares of company stock valued at $797,184. 5.00% of the stock is owned by insiders.

Institutional Trading of Evolus

A number of institutional investors have recently made changes to their positions in the business. State of Alaska Department of Revenue acquired a new stake in Evolus in the third quarter worth about $26,000. Larson Financial Group LLC boosted its holdings in Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Evolus in the fourth quarter worth about $34,000. Wexford Capital LP acquired a new stake in shares of Evolus during the 3rd quarter worth approximately $37,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Evolus by 340.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after purchasing an additional 5,691 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Price Performance

Evolus stock opened at $6.09 on Friday. The stock has a market cap of $401.09 million, a P/E ratio of -9.09 and a beta of 1.28. Evolus has a 1 year low of $3.86 and a 1 year high of $10.62. The firm’s 50 day moving average price is $5.14 and its 200-day moving average price is $5.61.

Evolus (NASDAQ:EOLS – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $73.14 million for the quarter, compared to analysts’ expectations of $72.52 million. During the same period last year, the company posted ($0.30) EPS. As a group, equities analysts expect that Evolus will post -0.41 EPS for the current year.

About Evolus

(Get Free Report)

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.